Castle Biosciences (CSTL) Change in Accured Expenses (2018 - 2026)

Castle Biosciences has reported Change in Accured Expenses for 9 years, with the latest figure at $7.8 million in Q2 2026.

• Quarterly Change in Accured Expenses rose 9.36% year-over-year to $7.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.9 million (down 48.58% YoY) and the FY2025 annual result came in at $5.7 million, up 58.78% from the prior year.
• Change in Accured Expenses rose to $7.8 million in Q2 2026 per CSTL's latest filing, from -$19.2 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $9.5 million in Q3 2025 and troughed at -$19.2 million in Q1 2026.
• A 5-year average of $612777.8 and a median of $4.9 million in 2022 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 137.8% in 2022, down 77.4% in 2022.
• Over 5 years, Change in Accured Expenses stood at $4.8 million in 2022, then jumped by 35.52% to $6.5 million in 2023, then fell by 25.34% to $4.9 million in 2024, then dropped by 21.56% to $3.8 million in 2025, then surged by 103.19% to $7.8 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $7.8 million, -$19.2 million, and $3.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.